15-min delayed · Jul 28, 3:45 PM ET · Get real-time quotes →
The Quantellect read.Of the 3 firms covering Aquestive Therapeutics Inc, 3 rate it Buy or better, 0 sit at Hold, and 0 rate it Sell or worse, a moderate buy consensus. Targets span $8.00 to $12.00, a moderate spread. The average target of $9.33 sits 148% above the current $3.77. The rating mix has stayed broadly stable, with Buy-side ratings easing from 4 to 3 over recent months. On the fundamentals, the Street sees revenue growth near 8% this year and 42% next, consensus EPS building from about $-0.12 next quarter toward $-0.45 the year after.Descriptive synthesis of third-party analyst data, not a Quantellect rating or recommendation.
ANALYST CONSENSUS3 ratings
Moderate Buy
Strong Buy00%
Buy3100%
Hold00%
Sell00%
Strong Sell00%
Based on 3 analysts giving stock ratings to Aquestive Therapeutics Inc.
As of Jul, 3 of 3 firms rate AQST a Buy (0 Hold, 0 Sell), the standing distribution of every covering firm's most recent active call.
AQST EPS & revenue forecast
EPS · NEXT QUARTER
$-0.12
Range $-0.14 – $-0.10 · 2 analysts · +5% YoY
Next period, 2 analysts expect Aquestive Therapeutics Inc to earn $-0.12 a share (range $-0.14 – $-0.10), versus $-0.11 a year earlier. Full-year consensus is $-0.42, growing to $-0.45 the year after.
REVENUE · NEXT QUARTER
$12.1M
Range $11.0M – $13.6M · 2 analysts · +17% YoY
Revenue is expected to reach $12.1M (range $11.0M – $13.6M), +17.0% year-over-year. Full-year consensus is $50.5M, rising to $71.9M next year.
Top analysts covering Aquestive Therapeutics Inc
Ranked by each analyst's overall Quantellect track record across all the stocks they cover, shown with their current call on AQST.
#1
Jason Butler
JMP Securities · Rank #22
Buy
$12.00+218.7% to target
Overall win rate
57%
+ Follow
#2
David Amsellem
Piper Sandler · Rank #95
Buy
$8.00+112.5% to target
Overall win rate
50%
+ Follow
#3
Kristen Kluska
Cantor Fitzgerald · Rank #162
Buy
$11.00+192.2% to target
Overall win rate
38%
+ Follow
#4
Francois Brisebois
Oppenheimer · Rank #186
Buy
$8.00+112.5% to target
Overall win rate
40%
+ Follow
#5
Raghuram Selvaraju
HC Wainwright & Co. · Rank #249
Buy
$10.00+165.6% to target
Overall win rate
37%
+ Follow
AQST stock forecast FAQ
What is AQST's average 12-month price target?+
The 3 analysts with a live target average $9.33 for Aquestive Therapeutics Inc over the next 12 months, ranging from a $12.00 high to a $8.00 low.
Is AQST stock a Buy, Sell or Hold right now?+
The current consensus is Moderate Buy. Of the 3 analyst ratings, 3 are Buy or Strong Buy, 0 are Hold, and 0 are Sell or Strong Sell.
What are the highest and lowest price targets for AQST?+
The Street-high target is $12.00 (JMP Securities), and the Street-low is $8.00 (Piper Sandler). The average of all 3 active targets is $9.33.
How many Wall Street analysts cover AQST?+
3 analysts have an active rating on Aquestive Therapeutics Inc, and 3 firms carry a live 12-month price target.
Who is the most accurate analyst covering AQST?+
Among analysts who currently cover AQST, Jason Butler of JMP Securities has the strongest overall Quantellect track record (Rank #22). Their current call is Buy with a $12.00 target.
What is Aquestive Therapeutics Inc's projected EPS for next quarter?+
The consensus estimate is $-0.12 per share (range $-0.14 – $-0.10) across 2 analysts. Full-year EPS is projected at $-0.42, rising to $-0.45 the following year.
How much revenue is Aquestive Therapeutics Inc expected to report next quarter?+
Consensus revenue is $12.1M (range $11.0M – $13.6M). Full-year revenue is projected at $50.5M, growing to $71.9M next year.
Have analysts been upgrading or downgrading AQST lately?+
As of Jul, 3 of 3 firms rate AQST a Buy (0 Hold, 0 Sell), the standing distribution of every covering firm's most recent active call.
How are the analysts on this page ranked?+
By each analyst's overall Quantellect track record — a sample-adjusted measure of how accurate their calls have been across every stock they cover. We do not rank on their AQST calls alone, since a single stock is too small a sample to be reliable.
Which data on this page is live, and how often does it update?+
Price and daily change are 15-minute delayed market data. Analyst ratings, targets, consensus and earnings estimates are aggregated from multiple data providers and refresh daily.
Disclaimer: Ratings, price targets, consensus and earnings estimates on this page describe third-party analyst research aggregated from multiple data providers and refreshed daily; price and daily change are 15-minute delayed. These are historical opinions, not recommendations, and nothing on this page, including The Quantellect read, is a rating, a price target, or investment advice from Quantellect. Always do your own research and consult a licensed financial advisor before making investment decisions.
